<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8F931DE8-96E4-4D9C-B5A9-3A61D8AD7A7B"><gtr:id>8F931DE8-96E4-4D9C-B5A9-3A61D8AD7A7B</gtr:id><gtr:firstName>Pervin</gtr:firstName><gtr:surname>Farooque</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501746"><gtr:id>AE021361-0A00-4F93-B944-67275D9F79B6</gtr:id><gtr:title>Molecular, Biochemical and Cellular Mechanisms of Aspirin-Sensitive Respiratory Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0501746</gtr:grantReference><gtr:abstractText>Patients with aspirin sensitive respiratory disease (ASRD) often have asthma that is difficult to control, rhinitis and severe nasal blockage due to nasal polyps. It is estimated that at least 10% of asthmatics are sensitive to aspirin.

We know that patients with ASRD produce increased quantities of chemicals called cysteinyl leukotrienes (CysLT) that cause inflammation in the breathing tubes and the nose. In this project we will take nasal polyps, that have been removed from patients with and without ASRD and use them to identify which cells produce CysLTs. 

We have also obtained clues that the increased amounts of CysLTs seen in ASRD may be due to reduced production or activity of an anti-inflammatory chemical called prostaglandin E2 (PGE2). So, we will break down nasal polyps and add aspirin to them and measure the amount of PgE2 produced. We will also look at the role of the different classes of PGE2 receptors and try to understand how PGE2 reduces CysLT production. 

Developing a working model of ASRD in the test-tube, will allow a far better understanding of how drugs to treat ASRD work and if PGE2 deficiency is confirmed this promises new hope for treatment with drugs which mimic its effects.</gtr:abstractText><gtr:technicalSummary>AIMS To elucidate the fundamental pathophysiological mechanisms underlying the triggering of adverse reactions to aspirin and related drugs in patients with aspirin-sensitive respiratory disease (ASRD).

OBJECTIVES

I will use nasal polyps as a readily accessible part of the respiratory tract to:

* Identify which inflammatory cell types are responsible for aspirin-induced cysteinyl leukotriene (CysLT) production in ASRD. 

* Evaluate whether deficiency of prostaglandin E2 (PGE2) production and/or reduced expression of PGE2 receptors (EP1-4) is implicated in the pathogenesis of ASRD. 

* Determine the site of action of PGE2 on the 5-lipoxygenase (5LO) pathway. 

* Establish proof of principle that stable PGE2 analogues may ameliorate ASRD

Surgically resected nasal polyps from patients with aspirin-sensitive and tolerant rhinosinusitis will be digested with collagenase after retaining a portion for immunohistochemistry. Macrophages, dendritic cells, neutrophils and B-cells will be depleted from the resulting suspension using magnetic bead technology. The remainder comprising of eosinophils and mast cells will be incubated in the presence and the absence of aspirin, using ionophore as a positive control. The release of CysLT, PGE2, histamine, eosinophil cationic protein and tryptase from both the eosinophil/mast cell suspension and the purified macrophages, dendritic cells, neutrophils and B-cells will be measured by commercially available ELISA or RIA. If as expected, the eosinophil/mast cell suspension is proven to be major source of CysLT, mast cell and eosinophil populations will be purified using established techniques and the above experiments repeated. In addition the purified eosinophil and mast cell populations will be cultured with specific agonists to EP1-4 and any inhibition of CysLT production correlated with the expression of EP1-4 on inflammatory leukocytes in sections of the same nasal polyps. EP1-4 expression will be determined using single and double sequential Immunohistochemistry. Supernatants from each reaction mixture will be subjected to reverse-phase high-performance liquid chromatography and 5LO pathway products will be separated and quantified. If the analysis suggests that PGE2 inhibits the activity of the whole 5LO pathway, translocation of cytosolic 5LO to the nucleus in ASRD will be investigated.

An in vitro model of ASRD will facilitate mechanistic understanding and inform new therapeutic approaches specifically for this condition. If deficient PGE2 signalling is identified as a critical factor in ASRD, this would encourage the development of stable PGE2 agonists in the relatively short term, for a disease that responds poorly to treatment and costs the NHS millions of pounds.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>212288</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Runner-up MRC Max Perutz Essay Prize</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>5AC971FA-78BC-474F-9A4A-BEB1832A0683</gtr:id><gtr:impact>Runner-up in MRc funded essay competition - ain of which was to detail research to the public, essay published in the guardian online

I do not think there were any notable impacts - although the work of the MRC Centre of Asthma, Allergy and Respiratory Science was highlighted</gtr:impact><gtr:outcomeId>15F4BEBAA76</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AFD8A310-C84D-4419-8E99-83F43DE8FAF1</gtr:id><gtr:title>T cells producing the anti-inflammatory cytokine IL-10 regulate allergen-specific Th2 responses in human airways.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b76e9d83fe8a9ae8690c5ae5c4595cc8"><gtr:id>b76e9d83fe8a9ae8690c5ae5c4595cc8</gtr:id><gtr:otherNames>Faith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>pm_16082_22_22671764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A3E8114-1180-44BC-9970-C261AF091010</gtr:id><gtr:title>Leukotriene E4: perspective on the forgotten mediator.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b60407215c7023f5e04e2d639b4c3d"><gtr:id>30b60407215c7023f5e04e2d639b4c3d</gtr:id><gtr:otherNames>Lee TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>9EE3E1D4904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0B32F89-E987-4449-AC6C-7333666E1506</gtr:id><gtr:title>Mechanisms of aspirin-sensitive respiratory disease--a two-compartment model.</gtr:title><gtr:parentPublicationTitle>International archives of allergy and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d796ab9fd102fa3b95ec6ed425087f8"><gtr:id>2d796ab9fd102fa3b95ec6ed425087f8</gtr:id><gtr:otherNames>Farooque S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1018-2438</gtr:issn><gtr:outcomeId>C74E11ABDBA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48E86322-45E2-49F2-95AB-BCF4DBCB4A29</gtr:id><gtr:title>1a,25-dihydroxyvitamin D3 promotes CD200 expression by human peripheral and airway-resident T cells.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86a171d3f9e86c44053f3a9b6627e3f3"><gtr:id>86a171d3f9e86c44053f3a9b6627e3f3</gtr:id><gtr:otherNames>Dimeloe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_16082_22_22334534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E996122-C2F6-4513-9B3B-89DBC91BDE68</gtr:id><gtr:title>Aspirin-sensitive respiratory disease.</gtr:title><gtr:parentPublicationTitle>Annual review of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1641550fb8e54420af13c3e0ba51de3"><gtr:id>a1641550fb8e54420af13c3e0ba51de3</gtr:id><gtr:otherNames>Farooque SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0066-4278</gtr:issn><gtr:outcomeId>5DD925799CC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FB21F5C-E848-44C1-B0D8-5AE13AC866D2</gtr:id><gtr:title>BSACI guidelines for the management of allergic and non-allergic rhinitis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d73b2359aaef337e7ad16c61e58220f"><gtr:id>2d73b2359aaef337e7ad16c61e58220f</gtr:id><gtr:otherNames>Scadding GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>C8DBF13AAB3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501746</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>